Physician profile
Paul A Walker
NPI 1922077056
$2,961.36
in general payments reported to CMS, 2019-2025
29 companies · $548 in 2025
The $548 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $705 · 2020: $190 · 2021: $183 · 2022: $449 · 2023: $329 · 2024: $557 · 2025: $548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,433.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $632.31 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $254.04 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $237.58 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $208.44 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $175.47 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $166.96 | 2022-2024 | Freestyle Libre 3 |
| Pfizer INC. | $160.63 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $154.44 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.12 | 2019-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.95 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $104.33 | 2019-2022 | |
| Dexcom, INC. | $61.32 | 2024-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $52.45 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.53 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $44.30 | 2019-2023 | Belsomra |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $42.35 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $42.28 | 2019 | |
| Boston Scientific Corporation | $42.26 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $41.33 | 2021-2024 | Austedo Xr, Austedo |
| Biohaven Pharmaceuticals, INC. | $33.58 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.68 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $28.12 | 2019 | |
| Avanir Pharmaceuticals, INC. | $27.58 | 2019 | |
| Amarin Pharma, INC. | $26.22 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $17.76 | 2024 | Belbuca |
| Biohaven Pharmaceutical Holding Company LTD. | $17.70 | 2022 | |
| Allergan, INC. | $16.38 | 2019 | |
| Phathom Pharmaceuticals, INC. | $14.76 | 2024 | Voquezna |
| Eisai INC. | $14.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.